64490-92-2
64490-92-2
Chemical Structure
Tolmetin sodium dihydrate
- CAS No.: 64490-92-2
- Formula:C15H18NNaO5
- Molecular Weight:315.30
IUPAC Name: sodium 2-(1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl)acetate dihydrate
InChIKey: QQILXENAYPUNEA-UHFFFAOYSA-M
SMILES: O=C(O[Na])CC1=CC=C(C(C2=CC=C(C)C=C2)=O)N1C.O.O
Biological Activity: Tolmetin sodium dihydrate is an orally active and potent COX inhibitor with IC50s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory drug (NSAID)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tolmetin sodium dihydrate | 99.94% | Tolmetin sodium dihydrate is an orally active and potent COX inhibitor with IC50s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory drug (NSAID). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolmetin sodium dihydrate (Standard) | ≥98% | Tolmetin (sodium dihydrate) (Standard) is the analytical standard of Tolmetin (sodium dihydrate). This product is intended for research and analytical applications. Tolmetin sodium dihydrate is an orally active and potent COX inhibitor with IC50s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory drug (NSAID). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. T D Warner, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8. [Content Brief]
- [2]. Morini G, et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs. Digestion. 2003;68(2-3):124-32. Epub 2003 Nov 7. [Content Brief]
